0001004878-16-000346.txt : 20160115
0001004878-16-000346.hdr.sgml : 20160115
20160115165536
ACCESSION NUMBER: 0001004878-16-000346
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160113
ITEM INFORMATION: Termination of a Material Definitive Agreement
FILED AS OF DATE: 20160115
DATE AS OF CHANGE: 20160115
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 161346003
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8kitem102prepay1-16.txt
FORM 8-K ITEM 1.02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2016
CEL-SCI CORPORATION
----------------------------------
(Exact name of registrant as specified in its charter)
Colorado 001-11889 84-0916344
----------------------- ------------------ ----------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Blvd. #802
Vienna, VA 22182
-----------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-----------------------------------------------
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-14c))
Item 1.02 Termination of a Material Definitive Agreement.
As of January 12, 2016 the Company owed the de Clara Trust (the "Trust")
$1,105,989, which amount included accrued and unpaid interest. The maturity date
of the loan from the Trust was July 6, 2018. Although the Trust could only
demand payment prior to July 6, 2018 upon giving the Company a minimum ten-day
notice, on January 13, 2016 the Company and the Trust agreed to the full
repayment of the loan. Following repayment, the Trust invested $1,110,000 in
shares of the Company's common stock and warrants. The de Clara Trust is
controlled by Geert Kersten, the Company's Chief Executive Officer and a
Director.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 15, 2016 CEL-SCI CORPORATION
By:/s/ Patricia B. Prichep
-----------------------------------
Patricia B. Prichep,
Senior Vice President of Operations